The Tumor Proteolytic Landscape: A Challenging Frontier in Cancer Diagnosis and Therapy
Open Access
- 3 March 2021
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 22 (5), 2514
- https://doi.org/10.3390/ijms22052514
Abstract
In recent decades, dysregulation of proteases and atypical proteolysis have become increasingly recognized as important hallmarks of cancer, driving community-wide efforts to explore the proteolytic landscape of oncologic disease. With more than 100 proteases currently associated with different aspects of cancer development and progression, there is a clear impetus to harness their potential in the context of oncology. Advances in the protease field have yielded technologies enabling sensitive protease detection in various settings, paving the way towards diagnostic profiling of disease-related protease activity patterns. Methods including activity-based probes and substrates, antibodies, and various nanosystems that generate reporter signals, i.e., for PET or MRI, after interaction with the target protease have shown potential for clinical translation. Nevertheless, these technologies are costly, not easily multiplexed, and require advanced imaging technologies. While the current clinical applications of protease-responsive technologies in oncologic settings are still limited, emerging technologies and protease sensors are poised to enable comprehensive exploration of the tumor proteolytic landscape as a diagnostic and therapeutic frontier. This review aims to give an overview of the most relevant classes of proteases as indicators for tumor diagnosis, current approaches to detect and monitor their activity in vivo, and associated therapeutic applications.This publication has 343 references indexed in Scilit:
- Functional imaging of proteases: recent advances in the design and application of substrate-based and activity-based probesCurrent Opinion in Chemical Biology, 2011
- The Legumain Protease‐Activated Auristatin Prodrugs Suppress Tumor Growth and Metastasis without ToxicityChemMedChem, 2010
- Physiology and pathophysiology of matrix metalloproteasesAmino Acids, 2010
- Matrix Metalloproteinase-Induced Epithelial-Mesenchymal Transition in Breast CancerJournal of Mammary Gland Biology and Neoplasia, 2010
- Matrix Metalloproteinases: Regulators of the Tumor MicroenvironmentCell, 2010
- Cathepsin G-mediated enhanced TGF-β signaling promotes angiogenesis via upregulation of VEGF and MCP-1Cancer Letters, 2010
- The tissue inhibitors of metalloproteinases (TIMPs): An ancient family with structural and functional diversityBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2010
- Rhomboid domain containing 2 (RHBDD2): A novel cancer-related gene over-expressed in breast cancerBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 2009
- ADAM proteases: ligand processing and modulation of the Notch pathwayCellular and Molecular Life Sciences, 2008
- Design of cell-permeable, fluorescent activity-based probes for the lysosomal cysteine protease asparaginyl endopeptidase (AEP)/legumainBioorganic & Medicinal Chemistry Letters, 2007